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OBJECTIVES This study sought to compare the utility of measurement of plasma brain natriuretic peptide
(BNP) and N-terminal brain natriuretic peptide (N-BNP) in the diagnosis of heart failure
(HF) in patients with acute dyspnea.
BACKGROUND Plasma BNP is useful in differentiating HF from other causes of dyspnea in the emergency
department. The N-terminal component of BNP has a longer half-life, and in HF increases
in plasma N-BNP are proportionately greater.
METHODS We studied 205 patients (average age 70 14 years) presenting to the emergency department
with acute dyspnea. Brain natriuretic peptide was analyzed using a point-of-care test and two
locally developed radioimmunoassays. N-terminal BNP was measured using a locally
developed radioimmunoassay and a commercially available assay. Final diagnosis of HF was
adjudicated by two cardiologists.
RESULTS Patients with HF (n  70) had higher mean levels of both hormones by all assays (p  0.001
for all). Results with all assays correlated closely (r values between 0.902 and 0.969). Subjects
with left ventricular (LV) dysfunction or left-sided valvular disease but no HF had
intermediate levels of BNP and N-BNP (lower than subjects with HF, and higher than
subjects without HF with no LV dysfunction or left-sided valvular disease) (p  0.01 for all).
Using optimum cut-offs, specificity for the diagnosis of HF ranged between 70% and 89%
(highest for the N-BNP assays). Sensitivity ranged between 80% and 94% (highest for the
point-of-care BNP assay).
CONCLUSIONS Measurement of BNP or N-BNP is useful in the diagnosis of HF in acute dyspnea.
Commercially available assays compare favorably with well-validated laboratory assays.
Differences in sensitivity and specificity may influence the assay choice in this setting. (J Am
Coll Cardiol 2003;42:728–35) © 2003 by the American College of Cardiology Foundation
Establishing the cause of shortness of breath in the acute
setting can be difficult (1). Measurement of plasma brain
natriuretic peptide (BNP), which is secreted by the heart in
response to increases in transmural pressure, is useful in
differentiating dyspnea due to heart failure (HF) from
dyspnea related to other factors (2,3). Recently, point-of-
care testing for plasma BNP has become available, and rapid
measurement of BNP in the emergency department has
been shown to be useful in establishing or excluding
congestive HF in patients with acute dyspnea (4,5).
The amino-terminal fragment of BNP (N-BNP) circu-
lates in human plasma. In health, N-BNP plasma levels are
similar to those of BNP but increase more strikingly in HF
(6,7). The ability of N-BNP measurement to aid in the
diagnosis of HF in acutely breathless patients has not been
assessed, and no study has compared measurement of BNP
with that of N-BNP in the diagnosis of HF in dyspneic
patients. An automated commercial assay for N-BNP
(Roche Diagnostics, Basel, Switzerland) has recently be-
come available.
This study was designed to compare the utility of mea-
surements of BNP and N-BNP in the diagnosis of HF in
acutely short-of-breath patients using a point-of-care BNP
test (Biosite Diagnostics, San Diego, California) and a
commercially available automated N-terminal BNP assay
(Roche Diagnostics) and, in addition, to compare these
assays with locally developed, well-validated radioimmuno-
assays for BNP and N-BNP.
METHODS
The protocol was approved by the Ethics Committee of the
Canterbury District Health Board, and participants gave
informed consent. Two hundred and five patients with
dyspnea presenting to the local emergency department were
enrolled. Patients were eligible for enrollment if dyspnea
was part of the reason for presentation and they were able to
give a blood sample within 8 h of arrival in the emergency
department. Data collected included results of medical
history and physical examination, blood tests, chest X-ray,
and other diagnostic tests. Echocardiograms were under-
taken as part of the standard clinical assessment in 171
patients, and an additional five patients had radionuclide
ventriculography.
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The final determination of the actual diagnosis was made
by two independent cardiologists who had access to all
relevant medical records, except the results of the natriuretic
peptide assays. The information available included emer-
gency department and inpatient medical records and results
of all investigations. The principles for diagnosis of HF
contained in the European Society of Cardiology guidelines
were followed (8), and all patients with HF fulfilled Fra-
mingham congestive HF score criteria. In cases of disagree-
ment (n 18), a third cardiologist was the final adjudicator.
Blood samples were collected into EDTA tubes, and a
sample was used immediately for analysis in the point-of-
care BNP test. The rest of the sample was placed immedi-
ately on ice, centrifuged within 30 min at 4°C, and the
plasma was stored at 80°C before assay.
The locally developed radioimmunoassays for N-BNP
and BNP were performed on extracted plasma. Plasma was
loaded on C18 reverse phase Sep-Pak cartridges, washed
with 6 ml of 0.1% trifluoroacetic acid and eluted with 2 ml
of 80% isopropanol in water. The extract was dried under an
air stream and reconstituted in buffer.
For N-BNP radioimmunoassay 100 l was incubated
with 100 l of radiolabeled N-BNP (amino acids 1-15 of
N-BNP) and 100 l of antiserum raised against N-BNP
(amino acids 1-15 N-BNP). After incubation for 24 h at
4°C, bound and free peptide was separated with a solid
phase second antibody reagent (SacCell donkey anti rabbit)
and the bound radioactivity counted in a gamma counter
(6). Within assay coefficients of variation were 50 pmol/l,
11.6%; 50 to 200 pmol/l, 3.9%; 200 pmol/l, 3.4%.
Between assay coefficients of variation were 11 pmol/l,
17.2%; 72 pmol/l, 8.5%; 139 pmol/l, 7.6%.
N-terminal brain natriuretic peptide was also measured
with a Roche Diagnostics proBNP assay on an Elecsys 2010
analyser. In this two-site assay 20 l of sample is incubated
with biotinylated polyclonal antibody plus a different poly-
clonal antibody labeled with a ruthenium complex. Both
antibodies are directed to the proBNP (amino acids 1-76 of
proBNP) region. Following incubation the bound fraction is
separated with streptavidin-coated microparticles and quan-
titated by chemiluminescence. Data provided by Roche
Diagnostics show total assay precision ranges from 1.8% at
800 pmol/l to 2.7% at 20.7 pmol/l and the detection limit is
0.6 pmol/l. Crossreactivity with other peptides including
BNP, amino-terminal proANP peptides, C-type natriuretic
peptide (CNP), and components of the renin-angiotensin
system were all 0.001%.
Brain natriuretic peptide was measured using two locally
developed radioimmunoassays. The first assay was designed
for research measurements (Research BNP), and the second
to provide more rapid results for clinical use (Clinical BNP).
For the Research BNP assay standard or extract (100 l)
was added to assay tubes plus 100 l of BNP antiserum
(Peninsula Laboratories, San Carlos, California) (9). The
assay was incubated for 22 to 24 h at 4°C, after which 100
l of 125I labeled BNP (10,000 cpm) was added and
incubated at 4°C for 22 to 24 h. Bound and free BNP were
separated using a solid phase second antibody method in
which 1 ml of 5% Sac-Cel (IDS, Boldon, United Kingdom)
plus 5% Dextran in assay buffer was added and then
centrifuged after 30 min at room temperature. The pellet
was then counted in a gamma counter.
The BNP antiserum had the following crossreactivities
(supplied by the manufacturer): BNP-32 (Human) 100%;
ANP1-28 (Human) 0.001%; BNP-26 (porcine)
0.001%; cANP (amino acids 4-23 of cANP) 0.007%.
Using this method, recoveries of BNP from human
plasma were 71% at 44 pmol/l, and 70% at 40 and 80
pmol/l. The assay had a mean detection limit of 0.75 pmol/l
after extraction when calculated over 30 assays. The between
assay coefficients of variation were 21.6% at 3.5 pmol/l,
17.6% at 6.7 pmol/l, and 17% at 21 pmol/l when measured
over 30 assays.
The Clinical BNP assay was identical to the Research
BNP assay except for substitution of a 3-h preincubation
with antibody at room temperature for the 22- to 24-h
preincubation at 4°C before addition of radiolabeled tracer
and a reduction in the second incubation time to 17 to 18 h
at 4°C (10). This change was effected to provide a rapid
assay that would deliver clinical results within 24 h but with
consequent lower sensitivity (higher detection limit) and
slightly higher set results brought about by the altered
incubation conditions.
Using this method, recoveries of BNP from human
plasma were 83% at 44 pmol/l. The assay had a mean
detection limit of 2.5 pmol/l after extraction and between
assay coefficients of variation were 10.8% at 24 pmol/l and
12.1% at 45 pmol/l when measured over 36 assays.
Brain natriuretic peptide was also measured with the
point-of-care Triage BNP Test (Biosite Diagnostics Inc.,
San Diego, California). Blood is added to a small test strip,
which filters out blood cells. The plasma moves by capillary
action into a reaction chamber where it is mixed and
incubated with fluorescent-labeled antibodies. Brain natri-
uretic peptide bound to labeled antibody is trapped further
along the capillary and quantified by fluorescence measure-
ment in a small reader. Data supplied by Biosite Diagnostics
show the recovery of BNP added to plasma ranges from
86% to 105%, with a detection limit of 1.4 pmol/l. Coeffi-
cients of variation (total imprecision) ranged from 10.1% at
8.3 pmol/l to 16.2% at 312 pmol/l. The assay did not
cross-react with atrial natriuretic peptide, CNP, N-ANP, or
N-BNP peptides, or angiotensin peptides.
Abbreviations and Acronyms
BNP  brain natriuretic peptide
CNP  C-type natriuretic peptide
HF  heart failure
LV  left ventricular
N-BNP  N-terminal brain natriuretic peptide
729JACC Vol. 42, No. 4, 2003 Lainchbury et al.
August 20, 2003:728–35 BNP and N-BNP in Acute Dyspnea
Statistical analysis. Comparisons between assay results
were determined by unpaired and paired t tests, as appro-
priate. Pearson’s correlation coefficients between assays were
determined on log transformed data. To determine the
capacity of measurements of BNP and N-BNP to differen-
tiate HF from other causes of dyspnea, we undertook
receiver-operating characteristic curve analysis and deter-
mined optimum cut-offs for sensitivity, specificity, positive
and negative predictive value, overall accuracy of the test,
and area under the receiver-operating characteristic curves.
We performed a stepwise multivariate logistic regression
analysis for each of the five assays used, to determine the
ability of BNP/N-BNP measurements to provide diagnostic
information in addition to standard clinical variables. For all
analyses, p  0.05 was considered statistically significant.
RESULTS
The characteristics of 205 patients are shown in Table 1. All
patients had shortness of breath as part of their reason for
presenting to the emergency department. The final diag-
nosis was HF in 70 patients (34%). The final clinical
diagnosis for the remaining 135 patients without HF is
given in Table 2.
Figure 1 presents the BNP and N-BNP values for the
patients with and without HF. For all assays, patients with
HF had significantly higher plasma levels of the measured
hormone (p 0.001 for all). Thirty of the patients with HF
had a left ventricular (LV) ejection fraction 45%, and in
this group the hormone levels by each assay were signifi-
cantly less than in those with HF and LV ejection fraction
45 but significantly higher than in those without HF (p
0.05 for all).
Twenty-three subjects were found to have significant LV
dysfunction or left-sided valvular disease (defined as a LV
Table 1. Patient Characteristics (n  205)
Characteristic Mean Age 70  14 Years
Male 100 (49%)
Coronary disease 88 (43%)








Elevated JVP 63 (31%)
Rales 98 (48%)
Third heart sound 24 (12%)
Bilateral ankle edema 67 (33%)
COPD  chronic obstructive pulmonary disease; JVP  jugular venous pressure;
NYHA  New York Heart Association functional class; PND  paroxysmal
nocturnal dyspnea.






Complications of carcinoma of the lung 9
Pulmonary embolism 3
Interstitial lung disease 5
Other* 36
*Other includes dyspnea associated with cardiac ischemia, anxiety, anemia, thyrotox-
icosis, undiagnosed and musculoskeletal chest pain, periearditis, and patients with no
definite final clinical diagnosis.
COPD  chronic obstructive pulmonary disease.
Figure 1. Brain natriuretic peptide (BNP) and N-terminal BNP (N-BNP)
values by five different assays in 135 subjects without heart failure (open
bars) and 70 patients with heart failure (striped bars). Values were
significantly higher by all assays for those with heart failure (p  0.001 for
all). Biosite  Biosite point-of-care BNP assay; Clinical  local clinical
BNP assay; Research local research BNP assay; Roche Roche N-BNP
assay; Local  local N-BNP assay. Bars indicate median value and
interquartile range, lines represent 10th and 90th percentile values, dots
represent outlying values.
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ejection fraction 45% or grade 3/4 mitral or aortic
regurgitation, or aortic stenosis with a peak Doppler-
derived gradient 50 mm Hg) but were considered not to
have HF as a cause for their acute dyspnea. In this group of
patients, values of BNP or N-BNP by all assays were
significantly higher than those from the group with no HF
and no LV systolic dysfunction or significant left-sided
valvular disease, and were significantly less by all assays than
the results from those with definite HF (Fig. 2) (p  0.05
for all comparisons). In these 23 patients, the final clinical
diagnoses were chronic obstructive pulmonary disease (n 
7), pneumonia (n  4), pulmonary thromboembolism (n 
2), interstitial lung disease (n  2), asthma (n  1), and
other diagnoses (n  7).
There were close correlations between all of the five
assays, ranging from an r value of 0.902 (for Biosite BNP vs.
Roche N-BNP results) to an r value of 0.969 (Roche
N-BNP vs. local N-BNP assay results) (Fig. 3) (p value for
correlations between all the assays was 0.0001). Correla-
tions between the Biosite BNP assay and the Clinical BNP
assay gave an r value of 0.911, and between the Biosite BNP
assay and the Research BNP assay an r value of 0.916 (p 
0.0001 for both). There were significant correlations be-
tween age and the results of all assays with r values ranging
from 0.58 for age versus local research BNP assay results to
0.636 for age versus local N-BNP results (p  0.01 for all
comparisons). The correlations between age and hormone
level was not significant among those with HF, but re-
mained significant for all assays among those without HF
(p  0.05). In addition, there were significant inverse
relationships between ejection fraction and the results of all
assays with r values ranging from 0.45 for Biosite versus
ejection fraction up to 0.53 for local research BNP versus
ejection fraction (p  0.01 for all comparisons). There were
no significant gender differences between hormone levels for
any of the assays.
Nineteen patients without HF had echocardiographically
derived tricuspid regurgitant velocities 3 m/s (average
3.5 m/s) yielding an estimated right ventricular systolic
pressure of 36 mm Hg greater than mean right atrial
pressure, and chronic obstructive pulmonary disease with an
otherwise structurally normal left ventricle. Hormone results
from these 19 subjects by all assays did not significantly
differ from the rest of the subjects without HF (p 0.05 for
all comparisons).
In multivariate models incorporating clinical parameters
(age, history of previous HF, presence of coronary artery
disease, elevated jugular venous pressure, rales, ankle edema,
and chest X-ray features of HF), hormone concentrations by
all assays remained significantly and independently predic-
tive of the final diagnosis of HF with p  0.005 for all
assays. Other clinical parameters that remained significantly
predictive of a final diagnosis of HF were history of previous
HF, peripheral edema, and chest X-ray evidence of HF in
all models (p  0.05 for all).
Figure 4 illustrates receiver-operating characteristic
curves for each of the five assays. The arrow indicates the
value for optimum sensitivity and specificity. Specificity at
optimum values was lowest with the Biosite BNP assay at
70% and highest for the local N-BNP assay at 89%.
Sensitivity was greatest with the Biosite BNP assay at 94%
and lowest with the Roche N-BNP assay at 80%. In general,
specificity appeared to be highest with the N-BNP assays,
Figure 2. Brain natriuretic peptide (BNP) and N-terminal BNP (N-BNP)
results from five different assays in 112 patients with no heart failure (open
bars), 23 patients with no heart failure but significant left ventricular
systolic dysfunction or left-sided valvular disease (striped bars), and 70
patients with congestive heart failure (dotted bars). By all assays, results
from the group with significant left ventricular dysfunction or left-sided
valvular disease and no heart failure were significantly higher than those
without heart failure and significantly less than those with heart failure
(p  0.01 for all comparisons). Biosite  Biosite point-of-care BNP assay;
Clinical  local clinical BNP assay; Research  local research BNP assay;
Roche  Roche N-BNP assay; Local  local N-BNP assay. Bars indicate
median value and interquartile range, lines represent 10th and 90th
percentile values, dots represent outlying values.
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although sensitivity was greater with the BNP assays.
Positive predictive values ranged from 62% with the Biosite
BNP assay to 79% with the local N-BNP assay, whereas
negative predictive values were uniformly 90% or greater,
being highest with the Biosite BNP assay at 96%. For both
commercially available assays, a range of values and the
associated specificity, sensitivity, positive and negative pre-
dictive values, and accuracy are given in Figure 4.
DISCUSSION
Our findings confirm that measurement of BNP is useful in
the diagnosis of HF in patients presenting to the emergency
department with shortness of breath (4,5). In addition, our
study demonstrates that plasma N-BNP is also useful in this
setting.
Across the five assays in this study, there was some
variability in the sensitivity and specificity. The point-of-
care Biosite BNP test yielded the highest sensitivity (94%)
and a somewhat lower specificity (70%) at the optimum
cut-off value. A point-of-care test with these characteristics
in the acute care setting allows a low result to confidently
exclude HF. In our study a value 60 pmol/l (208 pg/ml)
had a negative predictive value of 96%. In the previous
multicenter study by Maisel et al. (5), 1,586 patients
presenting to the emergency department with acute dyspnea
had point-of-care BNP measured, and in that population an
optimum cut-off of 34 pmol/l (100 pg/ml) was obtained
(sensitivity of 90% and a specificity of 76%). In the current
study, a value of 34 pmol/l (100 pg/ml) had higher sensi-
tivity (97%) but lower specificity (49%). The optimum
cut-off values and characteristics of the tests between the
two studies vary and likely relate to differences in the
Figure 3. Correlation between the results of the Roche N-terminal brain natriuretic peptide (N-BNP) assay and the Biosite brain natriuretic peptide (BNP)
assay (top) and Roche N-BNP assay and Local N-BNP assay (bottom). The assay results are log transformed. Biosite BNP  Biosite point-of-care BNP
assay; Roche N-BNP  Roche N-BNP assay; Local N-BNP  local N-BNP assay.
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Figure 4. Receiver-operating characteristic curves for the five assays for the diagnosis of heart failure. A range of cut-off values for the commercially available
Biosite brain natriuretic peptide (BNP) and Roche N-terminal brain natriuretic peptide (N-BNP) assays are given at the bottom of the figure; the
highlighted row represents the optimal value for specificity and sensitivity. ACC  overall accuracy of the test; AUC  area under the receiver-operating
characteristic curve; NPV  negative predictive value; PPV  positive predictive value; Spec  specificity; Sens  sensitivity. The arrows indicate the
optimum value for cut-off for specificity and sensitivity, defined as the point geometrically closest to perfect sensitivity and specificity. Overall accuracy of
the test is defined as the percentage of patients correctly classified as having heart failure or not. Clinical BNP  local clinical BNP assay; Biosite BNP 
Biosite point-of-care BNP assay; Research BNP local research BNP assay; Roche N-BNP Roche N-BNP assay; Local N-BNP local N-BNP assay.
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underlying populations. In particular, the average age of our
population was six years older than in the Maisel study (5).
These results emphasize the need to be aware of both the
variability of test performance across different populations
and the way in which test characteristics vary depending on
the chosen cut-off value.
N-terminal BNP increases more strikingly in HF than
does BNP and has a longer half-life (7,11). These features
could influence the diagnostic utility of measurement of
N-BNP in acutely short-of-breath patients. Both N-BNP
assays had somewhat higher specificity than the BNP assays,
while maintaining sensitivities of greater than 80%. Given
the longer plasma half-life of N-BNP, its diagnostic utility
may be influenced by duration of symptoms, and it may be
less affected by acute treatment, such as administration of
diuretics. Further study is required to clarify these issues.
Close correlations were observed between results from the
individual assays. Our own radioimmunoassays for both
BNP and N-BNP are well established and validated
(6,9,10). The close correlations between the results of the
two commercially available automated assays and our labo-
ratory assays provide support for the use of the commercial
assays in hospitals without extensive experience in measure-
ment of plasma peptides. A previous study by Fischer et al.
(12) has also noted close correlation between results of the
Biosite and Roche assays in a group of 50 normal subjects
and 100 patients with suspected HF.
As expected, there was a correlation between ejection
fraction and hormone level, and plasma levels of BNP are
known to reflect the severity of underlying cardiac dysfunc-
tion (13,14). A correlation between age and natriuretic
peptide levels has been previously noted (15), and this was
confirmed in the current study. This may be important for
the clinical application of BNP tests, and further studies
with larger numbers of subjects will be necessary to deter-
mine whether adjustment of optimum thresholds for the
diagnosis of HF are necessary based on age.
Maisel et al. (5) have previously shown that subjects with
LV dysfunction but without HF have values of plasma BNP
intermediate between those of patients with no HF and
normal LV function and those with shortness of breath due
to HF. This is confirmed in our current study, but we
included subjects with significant left-sided valvular disease
and no HF, along with significant LV dysfunction and no
HF, and found similar results. This may be clinically useful
in that subjects who are thought not to have HF but have
intermediate values of natriuretic peptides may require
further assessment for possible previously unrecognized
underlying structural cardiac disease.
In the acute setting, echocardiography is frequently not
available and the diagnosis of HF rests on clinical assess-
ment and chest X-ray (16). Multivariate analysis in the
current study suggests measurement of BNP and N-BNP
contributes significantly to the ability to diagnose HF. The
Biosite assay has the advantage of point-of-care applicabil-
ity; however, the commercially available Roche N-BNP
assay is available through an automated system, which can
give rapid turnaround times for results and run a large
number of samples simultaneously. The clinical application
of these and other commercial assays (which may become
available) will require care to avoid confusion resulting from
the different hormones measured and different cut-off values
suggested for the diagnosis of HF.
A significant number of patients had chronic obstructive
pulmonary disease and a number of these had a degree of
pulmonary hypertension without right HF, as demonstrated
by tricuspid regurgitant velocity measurement at echocardi-
ography. These patients did not have significantly elevated
levels of BNP or N-BNP. Increases in natriuretic peptide
plasma concentrations had been reported in subjects with
pulmonary hypertension compared with normal subjects,
but in the current study the levels were compared with those
in other unwell subjects with dyspnea (17). Numbers were
small but suggest that assessment of BNP is useful in
differentiating HF from chronic obstructive pulmonary
disease even in the presence of a degree of pulmonary
hypertension.
Conclusions. Our results support the use of BNP and
N-BNP measurement in the assessment of patients present-
ing to hospital with shortness of breath. The commercially
available assays compare favorably with well-validated lab-
oratory assays. The Biosite assay may be most useful in
excluding HF in this population, a useful characteristic in a
point-of-care test. N-terminal brain natriuretic peptide
assays appear to have somewhat better specificity and
positive predictive value.
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